Loading
Marinomed Biotech AG Stock: price and insider trades · Austria
No insider purchase over the last 90 days. The latest was filed 15 Apr 2026.
Marinomed Biotech AG: what insiders have been doing
Marinomed Biotech AG, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to FMA (OeKB OAM). Between 18 October 2025 and 18 October 2026, 5 insiders published 9 filings.
The flow runs one way only: 1 insider bought (1 purchase totalling €4,998) and nobody sold on the market. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 1 board member. The largest single trade was a purchase of €4,998 by Andreas Grassauer, published on 15 April 2026, equal to 0.053% of the market capitalisation.
Across the 49 companies tracked on its exchange, the median is 6 filings; at 9 filings, this issuer sits above that mark. Since 2019, the database holds 9 purchases and no sales by insiders of the company.
The clock since the last published purchase (15 April 2026) now reads 185 days. Most trades are made public on the day they happen. For comparison, MAR article 19 gives managers three business days to notify a trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from FMA (OeKB OAM). Past trades are no guide to future returns.
Insider Decl.
28
Thresholds
n/a
Buy Volume
€4M
9 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleAndreas Grassauer1 buy
Karl Mahler1 buy
Fundamental score
Ranked 3,428 of 24,148 companies
70.5
score / 100
Value58
Quality84
FCF yld-12%
Earn yld·
EV/EBITDA1.1x
ROE·
Gross mgn82%
Net mgn·
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€4.70
Analyst consensus
1 analysts2.00/5
€50.00Target €50.00(+964%)€50.00
Income statement
Revenue€7.7M
Gross profit€6.3M82% margin
EBITDA€19.0M247% margin
Net income€18.0M226.4% margin
Valuation
PER (trailing)0.5x
Beta-0.23
Balance sheet & cash
Market cap€9.4M
Total debt€11.4M
Free Cash Flow-€1.1M
Profitability & ownership
ROA-2.3%
% insiders23.8%
% institutions14.5%
Last declaration on 15 April 2026
Declarations28 total
▲
Same trade as the filing by Andreas Grassauer, counted once · View ↗
357 shares@ €14.000.053% mcap1.1% of flowShareISIN ATMARINOMED6FMA:247695
Canonical exit: 12 Jul 2026 (T+90)
357 shares@ €14.000.053% mcap1.1% of flowShareISIN ATMARINOMED6FMA:247691
Canonical exit: 12 Jul 2026 (T+90)
1,500 shares@ €14.000.22% mcap33.3% of flowShareISIN ATMARINOMED6FMA:247198
1,500 shares@ €14.0033.3% of flowShareISIN ATMARINOMED6FMA:247196
3,521 shares@ €14.000.52% mcap66.1% of flowShareISIN AT0000A3T5H4FMA:247192
●
Same trade as the filing by Andreas Grassauer, counted once · View ↗
33,032 shares@ €14.004.92% mcap98.9% of flowShareISIN AT0000A3T5H4FMA:247190
33,032 shares@ €14.004.92% mcap98.9% of flowShareISIN AT0000A3T5H4FMA:247186
33,032 shares@ €14.0049.7% of flowShareISIN AT0000A3T5H4FMA:247184
7,885 shares@ €14.701.23% mcap100.0% of flowShareISIN ATMARINOMED6FMA:217081
1,500 shares@ €14.000.22% mcap33.3% of flowShareISIN ATMARINOMED6FMA:216982
Canonical exit: 8 Apr 2025 (T+90)
5,053 shares@ €5.000.27% mcap33.9% of flowShareISIN ATMARINOMED6FMA:204313
Canonical exit: 17 Dec 2024 (T+90)
5,634.4 shares@ €37.56272.25% mcap34.6% of flowShareVienna Stock Exchange MICISIN ATMARINOMED6FMA:187466
Canonical exit: 19 Jul 2023 (T+90)
6,320 shares@ €63.204.25% mcap65.4% of flowShareVienna Stock Exchange MICISIN ATMARINOMED6FMA:178676
Canonical exit: 14 Dec 2022 (T+90)
632,000 shares@ €63.2020.2% of flowShareVienna Stock Exchange MICISIN ATMARINOMED6FMA:178670
Canonical exit: 14 Dec 2022 (T+90)
1,772,340 shares@ €88.61779.5% of flowShareVienna Stock Exchange MICISIN ATMARINOMED6FMA:166067
Canonical exit: 15 Mar 2022 (T+90)
16,200 shares@ €90.0015.52% mcap50.9% of flowShareOutside a trading venue NewsISIN ATMARINOMED6FMA:165265
Canonical exit: 2 Mar 2022 (T+90)
18,750 shares@ €75.0049.1% of flowShareOutside a trading venue NewsISIN ATMARINOMED6FMA:149376
Canonical exit: 16 Mar 2021 (T+90)
25 of 28 declarations
About Marinomed Biotech AG
Marinomed Biotech AG is a biopharmaceutical company focused on developing antiviral treatments and vaccines. It specializes in innovative solutions for viral diseases and respiratory infections.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
